开开实业：上半年净利润1180.1万元，同比下降61.94%

Core Viewpoint - The company reported a revenue increase of 10.95% year-on-year for the first half of 2025, but net profit attributable to shareholders decreased significantly by 61.94% due to the absence of compensation income from property acquisition in the previous year [1] Financial Performance - The company achieved an operating income of 543 million yuan in the first half of 2025 [1] - The net profit attributable to shareholders was 11.801 million yuan, a decline of 61.94% compared to the same period last year [1] - Basic earnings per share were reported at 0.049 yuan [1] Strategic Developments - The company is deepening its "big health" strategic transformation, leading to steady growth in the pharmaceutical sector [1] - The SPD project within the pharmaceutical segment generated approximately 290 million yuan in revenue, reflecting a year-on-year growth of 52% [1] Impact of Previous Year’s Income - The significant decrease in net profit is primarily attributed to the recognition of property acquisition compensation income of 28.4393 million yuan in the same period last year, which positively impacted net profit by 21.3293 million yuan [1]